Scientists test new drug cocktail for Tough-to-Treat cancers
NCT ID NCT01352962
Summary
This early-stage study tested the safety and best dose of a three-drug combination (gemcitabine, carboplatin, and lenalidomide) for patients with advanced bladder cancer and other solid tumors that had spread and were not responding to standard treatments. The main goal was to see how much of the new drug, lenalidomide, could be safely added to the two established chemotherapy drugs. Researchers also looked for early signs that the combination might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URETHRAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.